Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.66 |
| ▸ | MAOA | P21397 | 3/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557166 | 0.94 | MAOB (0.60) | MAOBMAOAALOX5RXRARXRB | |
| SCHEMBL1557204 | 0.86 | RXRA (0.65) | MAOBMAOAALOX5RXRARXRB | |
| SCHEMBL1557562 | 0.86 | MAOB (0.64) | MAOBMAOAALOX5RXRARXRB | |
| SCHEMBL16047643 | 0.81 | MAOB (0.66) | MAOBMAOAKMT2A | |
| SCHEMBL2909175 | 0.81 | MAOB (0.60) | MAOBMAOAALOX5RXRARXRB | |
| SCHEMBL13532065 | 0.79 | MAOB (0.57) | MAOBMAOAALOX5KMT2ASMN1; SMN2 | |
| SCHEMBL2321431 | 0.79 | KMT2A (0.56) | MAOBNR4A2KMT2A | |
| SCHEMBL7348486 | 0.79 | MAOB (0.83) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL12710187 | 0.78 | MAOB (0.55) | MAOBMAOAALOX5 | |
| SCHEMBL13532107 | 0.77 | MAOB (0.54) | MAOBMAOAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| US-8314147-B2 | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-8314147-B2 | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-8314147-B2 | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-20110086921-A1 | Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20110086921-A1 | Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20110086921-A1 | Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| EP-2307351-A2 | NOVEL SALTS OF (4-{Ý(5-{Ý(3-CHLOROPHENYL)METHYL¨OXY}-2-METHYLPHENYL)CARBONYL¨AMINO}-3-METHYLPHENYL)ACETIC ACID | Glaxo Group Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2009150118-A2 | NOVEL SALTS OF (4-{[(5-{[(3-CHLOROPHENYL)METHYL]OXY}-2-METHYLPHENYL)CARBONYL]AMINO}-3-METHYLPHENYL)ACETIC ACID | GLAXO GROUP LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150118-A2 | NOVEL SALTS OF (4-{[(5-{[(3-CHLOROPHENYL)METHYL]OXY}-2-METHYLPHENYL)CARBONYL]AMINO}-3-METHYLPHENYL)ACETIC ACID | GLAXO GROUP LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150119-A1 | NOVEL POLYMORPHIC FORMS OF (4-{[(5-{[(3-CHLOROPHENYL)METHYL]OXY}-2-METHYLPHENYL)CARBONYL]AMINO}-3-METHYLPHENYL)ACETIC ACID | GLAXO GROUP LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-2101751-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-09-23 | — | — | EP | disclosed |
| US-20080167377-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| US-20080167377-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| WO-2008071736-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071736-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167377-A1 | Novel compounds | F12, C1R, MRGPRX1 | MAOB 1261/4885MAOA 1891/4885ALOX5 3716/4885 |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | MAOB 1430/4885MAOA 1325/4885ALOX5 661/4885 |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | MAOB 1430/4885MAOA 1325/4885ALOX5 661/4885 |
| US-20110086921-A1 | Novel Polymorphic Forms of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid | CYP3A43, HLA-DRB1, UGT1A3 | MAOB 367/4885MAOA 304/4885ALOX5 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.